Heather Dalton, MD
The frontline setting patients with ovarian cancer has potential to change in the near future, with targeted and immunotherapy strategies showing promising signals of activity.
State of the Science Summit™ on Ovarian Cancer, Dalton, a gynecologic oncologist at Arizona Oncology, discussed the developing standard of care for the frontline treatment of patients with ovarian cancer.
OncLive: What is the standard first-line treatment option for patients with ovarian cancer?
: This is a controversial subject. There were many times where we thought we had it all figured out. With every trial, the water seems to get muddier regarding the standard of care. With the initial dose-dense regimen, we were excited about the improvement in overall survival that we saw that rivaled intraperitoneal (IP) chemotherapy. Everyone was understandably embracing of that regimen, but the results of the GOG 252 trial complicated that significantly as there was no difference in survival between the regimens.
... to read the full story